NASDAQ:CLRB - Cellectar Biosciences Stock Price, Forecast & News

Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB."

Cellectar Biosciences shares reverse split on the morning of Tuesday, July 17th 2018. The 1-10 reverse split was announced on Friday, July 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 13th 2018. An investor that had 100 shares of Cellectar Biosciences stock prior to the reverse split would have 10 shares after the split.

Cellectar Biosciences Inc (NASDAQ:CLRB) announced its quarterly earnings data on Tuesday, November, 12th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.38) by $0.04. View Cellectar Biosciences' Earnings History.

Cellectar Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Cellectar Biosciences.

3 analysts have issued 1 year price objectives for Cellectar Biosciences' shares. Their forecasts range from $3.00 to $10.00. On average, they anticipate Cellectar Biosciences' stock price to reach $6.33 in the next year. This suggests a possible upside of 191.9% from the stock's current price. View Analyst Price Targets for Cellectar Biosciences.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectar Biosciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellectar Biosciences.

News coverage about CLRB stock has been trending very negative on Friday, InfoTrie reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cellectar Biosciences earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Cellectar Biosciences.

Cellectar Biosciences saw a increase in short interest in January. As of January 31st, there was short interest totalling 311,900 shares, an increase of 88.9% from the January 15th total of 165,100 shares. Based on an average daily volume of 123,600 shares, the days-to-cover ratio is currently 2.5 days. Currently, 3.4% of the shares of the stock are short sold. View Cellectar Biosciences' Current Options Chain.

Some companies that are related to Cellectar Biosciences include Infinity Pharmaceuticals (INFI), Checkpoint Therapeutics (CKPT), Elite Pharmaceuticals (ELTP), Stealth BioTherapeutics (MITO), Onconova Therapeutics (ONTX), Eyenovia (EYEN), Q BioMed (QBIO), Entasis Therapeutics (ETTX), Leap Therapeutics (LPTX), Trevena (TRVN), Chembio Diagnostics (CEMI), Soligenix (SNGX), Catabasis Pharmaceuticals (CATB), Cumberland Pharmaceuticals (CPIX) and CTI BioPharma (CTIC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International (S), Bombardier (BDRBF), Encana (ECA), Bombardier, Inc. Class B (BBD.B), Bonavista Energy (BNP) and Hudbay Minerals (HBM).

Cellectar Biosciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (2.12%) and Game Plan Financial Advisors LLC (0.46%). Company insiders that own Cellectar Biosciences stock include James V Caruso, Jarrod Longcor and Stephen A Hill. View Institutional Ownership Trends for Cellectar Biosciences.

CLRB stock was purchased by a variety of institutional investors in the last quarter, including Game Plan Financial Advisors LLC and Renaissance Technologies LLC. Company insiders that have bought Cellectar Biosciences stock in the last two years include James V Caruso and Jarrod Longcor. View Insider Buying and Selling for Cellectar Biosciences.

Shares of CLRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CLRB stock can currently be purchased for approximately $2.17.

Cellectar Biosciences has a market capitalization of $20.39 million. The biopharmaceutical company earns $-13,240,000.00 in net income (profit) each year or ($4.66) on an earnings per share basis. Cellectar Biosciences employs 7 workers across the globe.View Additional Information About Cellectar Biosciences.

The official website for Cellectar Biosciences is http://www.cellectar.com/.

Cellectar Biosciences' mailing address is 100 CAMPUS DRIVE, FLORHAM PARK NJ, 07932. The biopharmaceutical company can be reached via phone at 608-441-8120 or via email at [email protected]